Scientific deep-dive
GLP-1 Drugs and Asthma Risk: Read the Severity Column, Not the Headline
A cohort of people with type 2 diabetes found an adjusted hazard ratio of 0.67 for developing asthma on a GLP-1 — but the association weakened as severity rose and disappeared at cases requiring intubation.
A cohort study of people with type 2 diabetes reported that those taking a GLP‑1 were less likely to develop asthma — adjusted hazard ratio 0.67.[1] Read one row further and the picture complicates. The association was strongest for the mildest asthma and weakest for the most severe, and at the severest endpoint of all — cases requiring a breathing tube — it vanished. That pattern is worth more of your attention than the headline number.
What the study found
Researchers used Taiwan’s National Health Insurance database from 2011 to 2015, excluding anybody who already had asthma. Out of a cohort of 1,936,512 people with type 2 diabetes, 1,345 were treated with a GLP‑1 receptor agonist. Mean follow-up was 2.92 years.[1]
| Endpoint | HR | 95% CI |
|---|---|---|
| Asthma overall | 0.67 | 0.45–0.76 |
| No acute exacerbations | 0.55 | 0.37–0.62 |
| With acute exacerbations | 0.59 | 0.39–0.66 |
| Status asthmaticus | 0.83 | 0.56–0.93 |
| Requiring endotracheal intubation | 0.96 | 0.65–1.09 |
The authors describe this as a protective trend across severity levels, except in cases requiring intubation. That is accurate. It is also possible to read the same column as a gradient that weakens steadily the sicker the endpoint gets, until at the top it is indistinguishable from no effect at all.
What 1,345 people means
The exposed group is 1,345 out of nearly two million. New-onset asthma in adults with diabetes is uncommon, so the number of actual asthma cases inside that exposed group will be small, and the confidence intervals reflect it. Nothing about a national database changes the fact that the drug arm here is smaller than many single-center trials.
The years matter too. The data run 2011 to 2015, which predates semaglutide and tirzepatide in general use. Whatever this cohort was taking, it was mostly the earlier drugs in the class, and the authors’ suggestion of a class effect is an inference rather than a demonstration for the drugs most people are prescribed today.
And COPD, where we found nothing
COPD is usually paired with asthma when this question is raised. We could not find a cohort or trial reporting COPD outcomes for GLP‑1 receptor agonists that would support a sentence here. Rather than borrow the asthma result and let it stand in, we are saying so: on COPD, this register has nothing to report.
What to do with it
- No GLP-1 is approved to prevent or treat asthma, and nothing here suggests taking one for that reason.
- This is a single retrospective cohort with 1,345 exposed people and no randomization.
- The severity gradient runs in the direction that confounding would produce, which is the main reason to hold the result loosely.
- If you have asthma and are considering a GLP-1 for weight or diabetes, this is not a reason for concern either — the study found no signal of harm.
- ⚠ Inhaled therapy is not something to change on the strength of a records study. That is a conversation with whoever manages your asthma.
For the airway condition where a GLP‑1 does hold an approved indication and a randomized trial, see Zepbound for sleep apnea.
Frequently Asked Questions
References
- 1.Cheng YS, Chung CH, Kuo SM, et al. Glucagon-like peptide-1 receptor agonists linked to a reduced risk of developing asthma among patients with type 2 diabetes Therapeutic Advances in Endocrinology and Metabolism. 2025. PMID: 41425689.
Related research
Amycretin: A 24% Weight Figure, and the Trial It Came From
Once-weekly amycretin produced an estimated 24.3% bodyweight reduction at 36 weeks against 1.1% on placebo — from a single-site phase 1b/2a study of 125 people whose primary endpoint was counting adverse events.
5 min read
Bone Density on a GLP-1: The Trial That Compared It Against Exercise
A four-arm randomized trial found liraglutide alone lost hip and spine bone density relative to exercise — while the combination arm lost the most weight and held bone density level with placebo.
7 min read
Danuglipron: The Oral GLP-1 That Worked, and That 6 in 10 Did Not Finish
Danuglipron's phase 2b study in 628 adults with obesity produced up to 12.9% weight loss against placebo — and 39.3% of participants completed treatment, with about 38% stopping for adverse events.
5 min read
Dry Mouth on a GLP-1: Three Published Cases, and What to Tell Your Dentist
The published evidence that GLP-1 drugs cause dry mouth is three case reports. Nobody has measured how often it happens — but reduced saliva raises decay risk regardless of cause, which is the part worth acting on.
5 min read
Eating Too Little on a GLP-1: What the Deficiency Data Show
Across 480,825 adults, more than 60% were consuming below estimated requirements, vitamin D deficiency reached 13.6% at a year, and ferritin ran 26–30% below an active comparator.
7 min read
GLP-1 Drugs After 65: Strength, Not Just Weight
Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite — and no guidelines exist for this age group.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Trimi Health
Knowing which pharmacy fills the vial — it names VialsRx
Pricing Compare
Get started →ShedRx
Oral orforglipron alongside the injectables
Pricing Compare
Get started →bmiMD
Starting below a standard dose, with microdose tiers
Pricing Compare
Get started →